A World-First in Genomics, a Saliva Test to Predict Complications Associated with Type 2 Diabetes
A new agreement has been signed between OPTITHERA, ELNA Medical Group, and Génome Québec as part of Genome Canada’s Genomic Applications Partnership Program (GAPP).
